Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma

Trial Profile

An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 21 Jun 2020 Results (N=1040) of pooled analysis from nine clinical studies: ACE-CL-007, ACE-CL-309, ACE-CL-001, 15-H-0016, ACE-LY-002, ACE-LY-003, ACE-LY-004, ACE-MY-001, ACE-WM-001 assessing safety profile of acalabrutinib monotherapy in multiple B-cell malignancies presented at the 25th Congress of the European Haematology Association
    • 18 Jun 2019 Status changed from active, no longer recruiting to completed.
    • 17 Dec 2018 Results of population pharmakoinetics of Acalabrutinib and its Active Metabolite using data from this and other 12 studies, published in the Clinical Pharmacokinetics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top